文献速递脑血管病神经重症与神经感染

尽管大血管造影再灌注,微血管组织再灌注受损(无复流)的患病率与意义

Prevalence and Significance of Impaired Microvascular Tissue Reperfusion Despite Macrovascular Angiographic Reperfusion (No-Reflow).
PubMed 文献 · Neurology · 2021-12-14

该研究汇总3项国际随机对照取栓试验,在130例前循环大血管闭塞且最终造影达到2c-3级再灌注的患者中,25.3%在24小时灌注影像上出现无复流。无复流与出血转化、梗死增长、24小时NIHSS改善差及90天依赖或死亡相关。

要点

  • 取栓后造影完全再灌注患者中,约四分之一在24小时灌注影像上存在无复流。
  • 无复流与出血转化、梗死增长、24小时神经功能改善差及90天不良预后相关。
  • 无复流可通过临床可及的CT或MRI灌注序列识别。

核心结论

  • 人类脑无复流常见,可通过特征性灌注影像表现识别,并与治疗后并发症及依赖或死亡相关。

研究设计与样本

  • 汇总分析EXTEND-IA、EXTEND-IA TNK和EXTEND-IA TNK Part 2三项国际随机对照取栓试验。
  • 纳入最终造影eTICI 2c-3级的前循环大血管闭塞取栓患者,并有24小时CT或MRI灌注随访,共130例。

主要发现

  • 33/130例(25.3%)存在无复流区域,中位占梗死体积60.2%(IQR 47.8%-70.7%)。
  • 无复流累及皮质下(26/33,78.8%)和皮质(10/33,30.3%)区域。
  • 无复流患者梗死区相对脑血容量中位侧间降低25.2%(IQR 16.4%-32.2%,p<0.00001),相对脑血流量降低19.1%(IQR 3.9%-28.3%,p=0.00011),平均通过时间相似(中位-3.3%,IQR -11.9%至24.4%,p=0.24)。
  • 无复流与出血转化(aOR 1.79,95%CI 2.32-15.57,p=0.0002)、梗死增长(β=11.00,95%CI 5.22-16.78,p=0.00027)、24小时NIHSS改善较差(β=-4.06,95%CI 6.78-1.34,p=0.004)及90天mRS依赖或死亡(aOR 3.72,95%CI 1.35-10.20,p=0.011)相关。

关键数值与推荐

  • 无复流定义为梗死区内相对脑血容量或血流图上持续低灌注,且与镜像同源区不对称>15%,并排除颈动脉狭窄或再闭塞。
  • 最终造影eTICI 2c-3级定义为大血管造影再灌注。

临床怎么用

  • 作者认为,无复流可通过临床可及的CT或MRI灌注序列检测,并与治疗后并发症及不良功能结局相关。
  • 作者提出,需进一步研究评估无复流在造影再灌注后继发性损伤中的作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The relevance of impaired microvascular tissue-level reperfusion despite complete upstream macrovascular angiographic reperfusion (no-reflow) in human stroke remains controversial. We investigated the prevalence and clinical-radiologic features of this phenomenon and its associations with outcomes in 3 international randomized controlled thrombectomy trials with prespecified follow-up perfusion imaging. METHODS: In a pooled analysis of the Extending the Time for Thrombolysis in Emergency Neurological Deficits-Intra-Arterial (EXTEND-IA; ClinicalTrials.gov NCT01492725), Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke (EXTEND-IA TNK; NCT02388061), and Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2; NCT03340493) trials, patients undergoing thrombectomy with final angiographic expanded Treatment in Cerebral Infarction score of 2c to 3 score for anterior circulation large vessel occlusion and 24-hour follow-up CT or MRI perfusion imaging were included. No-reflow was defined as regions of visually demonstrable persistent hypoperfusion on relative cerebral blood volume or flow maps within the infarct and verified quantitatively by >15% asymmetry compared to a mirror homolog in the absence of carotid stenosis or reocclusion. RESULTS: Regions of no-reflow were identified in 33 of 130 patients (25.3%), encompassed a median of 60.2% (interquartile range 47.8%-70.7%) of the infarct volume, and involved both subcortical (n = 26 of 33, 78.8%) and cortical (n = 10 of 33, 30.3%) regions. Patients with no-reflow had a median 25.2% (interquartile range 16.4%-32.2%, p < 0.00001) relative cerebral blood volume interside reduction and 19.1% (interquartile range 3.9%-28.3%, p = 0.00011) relative cerebral blood flow reduction but similar mean transit time (median -3.3%, interquartile range -11.9% to 24.4%, p = 0.24) within the infarcted region. Baseline characteristics were similar between patients with and those without no-reflow. The presence of no-reflow was associated with hemorrhagic transformation (adjusted odds ratio [aOR] 1.79, 95% confidence interval [CI] 2.32-15.57, p = 0.0002), greater infarct growth (β = 11.00, 95% CI 5.22-16.78, p = 0.00027), reduced NIH Stroke Scale score improvement at 24 hours (β = -4.06, 95% CI 6.78-1.34, p = 0.004) and being dependent or dead at 90 days as assessed by the modified Rankin Scale (aOR 3.72, 95% CI 1.35-10.20, p = 0.011) in multivariable analysis. DISCUSSION: Cerebral no-reflow in humans is common, can be detected by its characteristic perfusion imaging profile using readily available sequences in the clinical setting, and is associated with posttreatment complications and being dependent or dead. Further studies evaluating the role of no-reflow in secondary injury after angiographic reperfusion are warranted. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that cerebral no-reflow on CT/MRI perfusion imaging at 24 hours is associated with posttreatment complications and poor 3-month functional outcome.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ng FC, Churilov L, Yassi N, et al. Prevalence and Significance of Impaired Microvascular Tissue Reperfusion Despite Macrovascular Angiographic Reperfusion (No-Reflow). Neurology. 2021. PMID: 34906976. doi:10.1212/WNL.0000000000013210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。